摘要
目的探讨伊达比星治疗初治急性髓系白血病的疗效。方法收集2012年12月~2014年2月我院诊断为急性髓系白血病的患者作为本次研究对象,按住院单双号顺序分为2组,研究组,对照组各40例,研究组接受伊达比星＋阿糖胞苷巩固治疗,对照组接受柔红霉素＋阿糖胞苷巩固治疗。对比（1）研究组和对照组中性粒细胞恢复时间、治疗期间白细胞最低值。（2）研究组和对照组6个月无病生存率。结果（1）研究组和对照组中性粒细胞恢复时间、治疗期间白细胞最低值分别为[（15.4±3.9）d、（1.4±0.6）109/L]、[（8.6±2.5）d、（2.3±0.9）109/L],差异有统计学意义（P〈0.05）。（2）研究组和对照组6个月无病生存率分别为84%、62%,差异有统计学意义（P〈0.05）。结论本次研究认为伊达比星对初治急性髓系白血病疗效肯定。
Objective To evaluate the clinical efficacy of idarubicin therapy for the initial treatment of acute myeloid leukemia. Methods Collected acute myeloid leukemia patients diagnosed in the hospital as the subject from December 2012 to February 2014. These patients were divided into two groups according to their hospitalization ID（even and odd numbers）. Treatment group and control group had 40 cases respectively. Treatment group were treated with combination of Idarubicin and cytarabine in postoperative treatment while control group for combination of daunorubicin and cytarabine. Comparison of（1）neutrophil recovery time,the lowest value of white blood cells in the treatment.（2） the disease free survival rate within 6 months. Results（1） neutrophil recovery time and the lowest value of white blood cells in treatment group and control group were[（15.4±3.9）d、（1.4±0.6）109/L]、[（8.6±2.5）d、（2.3±0.9）109/L]respectively. The difference was statistically significant（P〈0.05）.（2）the diseasefree survival rates in treatment group and control group were 84% and 62%,respectively,and the difference was statistically significant（P〈0.05）. Conclusion This study suggests that idarubicin is effective in the initial treatment of acute myeloid leukemia.
出处
《中国卫生标准管理》
2016年第6期98-99,共2页
China Health Standard Management
